



**For Immediate Release**  
CONTACT: Carol Klimas 480-505-4527  
carolk@offmadisonave.com  
www.ProvistaLS.com

## **PROVISTA LIFE SCIENCES EXPANDS TO KEEP PACE WITH GROWTH AND TO HOUSE CORPORATE OPERATIONS AND LABORATORY UNDER ONE ROOF**

Phoenix (February 11, 2008) – Provista Life Sciences LLC (PLS), a diagnostic development and commercialization company, recently expanded its operations and moved into a 14,000 square-foot facility located at 6225 N. 24th St., Suite 150, in Phoenix. The expansion allows both the corporate headquarters and diagnostic laboratory, which were housed in separate locations prior to the move, to operate out of a single location.

“The expansion is in direct response to the significant growth that Provista Life Sciences has achieved over the past year,” said William Gartner, CEO of Provista Life Sciences. “Combining both facilities under one roof will greatly assist our continuing efforts to develop and commercialize socially relevant and clinically needed diagnostic technologies”

Provista Life Sciences saw the need to bring the two facets of the company together due to the growth it was experiencing in its diagnostic division, Provista Diagnostics. Housing both the state-of-the-art laboratory and company headquarters under one roof allows the company to focus its resources and manage operations more efficiently. Moreover, operating out of a single, larger facility allows for collaboration between laboratory and operation staff and provides room for anticipated growth as its clinical studies expand and additional diagnostic tests are introduced to the market.

Provista Life Sciences has recently made significant advances in the field of diagnostic testing, specifically in the areas of breast cancer, Alzheimer’s disease and women’s reproductive cancers. The BT Test™, a blood test for the early detection of breast cancer, has recently been made available to all women in Arizona. The company’s blood test to assist in the early detection of Alzheimer’s disease, called the LymPro Test™, is set to launch by mid-2008, and a third diagnostic test, called the RCP Test™, is currently under development and is for the early detection of women’s estrogen-related cancers, such as ovarian, uterine and cervical.

More information on Provista Life Sciences and all of its diagnostic tests can be found on the company Web site: [www.ProvistaLS.com](http://www.ProvistaLS.com).

### About Provista Life Sciences

Provista Life Sciences is a biotechnology diagnostics development and commercialization organization that provides the scientific and operating management resources to rapidly advance the development and introduction of novel diagnostics technologies into the domestic and global marketplace. For more information, visit the company’s Web site at [www.ProvistaLS.com](http://www.ProvistaLS.com) or call 602-224-5500.